相似文献
1
Immunity and hypertension: New targets to lighten the pressure.
Br J Pharmacol. 2019 Jun;176(12):1813-1817. doi: 10.1111/bph.14659.
2
Monocytes as immune targets in arterial hypertension.
Br J Pharmacol. 2019 Jun;176(12):1966-1977. doi: 10.1111/bph.14389. Epub 2018 Jul 14.
3
Salt, inflammation, IL-17 and hypertension.
Br J Pharmacol. 2019 Jun;176(12):1853-1863. doi: 10.1111/bph.14359. Epub 2018 Jun 15.
4
Mechanisms of hypertension in autoimmune rheumatic diseases.
Br J Pharmacol. 2019 Jun;176(12):1897-1913. doi: 10.1111/bph.14604. Epub 2019 Mar 18.
5
Immune cell trafficking, lymphatics and hypertension.
Br J Pharmacol. 2019 Jun;176(12):1978-1988. doi: 10.1111/bph.14370. Epub 2018 Jun 25.
6
Targeting inflammation to reduce cardiovascular disease risk.
Br J Pharmacol. 2017 Nov;174(22):3895-3897. doi: 10.1111/bph.14039.
7
The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.
Br J Pharmacol. 2019 Jun;176(12):1839-1852. doi: 10.1111/bph.14481. Epub 2018 Sep 25.
8
The role of autoimmune reactivity induced by heat shock protein 70 in the pathogenesis of essential hypertension.
Br J Pharmacol. 2019 Jun;176(12):1829-1838. doi: 10.1111/bph.14334. Epub 2018 May 22.
9
Human monocyte transcriptional profiling identifies IL-18 receptor accessory protein and lactoferrin as novel immune targets in hypertension.
Br J Pharmacol. 2019 Jun;176(12):2015-2027. doi: 10.1111/bph.14364. Epub 2018 Jun 21.
10
Role of immune cells in hypertension.
Br J Pharmacol. 2019 Jun;176(12):1818-1828. doi: 10.1111/bph.14427. Epub 2018 Jul 20.
引用本文的文献
1
Trained innate immunity as a potential link between preeclampsia and future cardiovascular disease.
Front Endocrinol (Lausanne). 2024 Dec 16;15:1500772. doi: 10.3389/fendo.2024.1500772. eCollection 2024.
本文引用的文献
1
Immune mechanisms of hypertension.
Nat Rev Immunol. 2019 Aug;19(8):517-532. doi: 10.1038/s41577-019-0160-5.
2
Mechanisms of hypertension in autoimmune rheumatic diseases.
Br J Pharmacol. 2019 Jun;176(12):1897-1913. doi: 10.1111/bph.14604. Epub 2019 Mar 18.
3
1,2,3,4,6-Penta-O-galloyl-β-d-glucose modulates perivascular inflammation and prevents vascular dysfunction in angiotensin II-induced hypertension.
Br J Pharmacol. 2019 Jun;176(12):1951-1965. doi: 10.1111/bph.14583. Epub 2019 Mar 14.
4
Childhood adversity and mechanistic links to hypertension risk in adulthood.
Br J Pharmacol. 2019 Jun;176(12):1932-1950. doi: 10.1111/bph.14576. Epub 2019 Mar 3.
5
Th1-type immune responses to Porphyromonas gingivalis antigens exacerbate angiotensin II-dependent hypertension and vascular dysfunction.
Br J Pharmacol. 2019 Jun;176(12):1922-1931. doi: 10.1111/bph.14536. Epub 2018 Dec 26.
6
Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Cardiovasc Res. 2019 Mar 15;115(4):776-787. doi: 10.1093/cvr/cvy252.
7
Adaptive immunity and IL-17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice.
Br J Pharmacol. 2019 Jun;176(12):2002-2014. doi: 10.1111/bph.14509. Epub 2018 Dec 18.
8
The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.
Br J Pharmacol. 2019 Jun;176(12):1839-1852. doi: 10.1111/bph.14481. Epub 2018 Sep 25.
9
Inflammatory mediators: a causal link to hypertension during preeclampsia.
Br J Pharmacol. 2019 Jun;176(12):1914-1921. doi: 10.1111/bph.14466. Epub 2018 Sep 28.
10
Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?
Br J Pharmacol. 2019 Jun;176(12):1864-1879. doi: 10.1111/bph.14438. Epub 2018 Aug 9.
Zotero 插件